$SKIN

SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. skin-20260810 FALSE 0001818093 Nasdaq 0001818093 2026-08-10 2026-08-10 0001818093 us-gaap:CommonStockMember 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exch

SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-2026q2xearnings.htm EX-99.1 Document Exhibit 99.1 SkinHealth Systems Reports Second Quarter 2026 Financial Results Long Beach, Calif., August 6, 2026 – SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafaci

SkinHealth Systems Inc. (SKIN) said the U.S. FDA cleared its SkinStylus microneedling device to improve periorbital wrinkles in adults 22+ across all Fitzpatrick skin types. The clearance expands approved uses, including facial acne scars and hypertrophic abdominal scars. SKIN shares closed Tuesday at $1.11, up 47.04%, after-hours $1.02.

SkinHealth Systems (NASDAQ: SKIN) said the FDA cleared its SkinStylus SteriLock microneedling device to improve periorbital wrinkles in adults 22+ for all Fitzpatrick skin types. The clearance expands indications to include facial acne scars and abdominal hypertrophic scars. The company cited 2025 U.S. microneedling spend of about $330M (+33% YoY) and noted Hydrafacial pairing interest.

SkinHealth Systems Inc. (SKIN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. skin-20260610 FALSE 0001818093 Nasdaq 0001818093 2026-06-10 2026-06-10 0001818093 us-gaap:CommonStockMember 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exch

SkinHealth Systems (NASDAQ: SKIN) said it refreshed its Keravive scalp treatment as HydraScalp® with Keravive™, adding Purify™ and Nourish™ scalp tips and using its Vortex-Fusion™ technology plus biomimetic peptides. The company cites clinical results: 75% reported improved hair fullness after 8 weeks, 82% healthier-looking hair after 3 months, and 6x more hydrated scalp after one treatment. The treatment is available at select Hydrafacial providers.

Explore how Beauty Health's (SKIN) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Although the revenue and EPS for Beauty Health (SKIN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Beauty Health (SKIN) delivered earnings and revenue surprises of -12.50% and +2.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth